| Product Name | SensoLyte ® 490 HIV Protease Assay Kit *Fluorimetric* |
| Size | 1 kit |
| Catalog # | AS-71127 |
| US$ | $663 |
HIV protease (PR) is identified as an important drug-screening target for the design of selective acquired immunodeficiency syndrome (AIDS) therapeutics. The SensoLyte® 490 HIV Protease Assay Kit uses an optimized FRET peptide substrate for a continuous measurement of HIV protease activities. This FRET-based fluorogenic substrate is derived from a natural processing site for HIV-1 PR. Incubation of the recombinant HIV-1 PR with this substrate results in specific cleavage and a time-dependent increase in fluorescence intensity that is linearly related to the extent of substrate hydrolysis. Because of its simplicity and precision in the determination of reaction rates required for kinetic analysis, this kit offers many advantages over the commonly used HPLC or electrophoresis-based assays for peptide substrate hydrolysis by retroviral PRs.The kit contains: EDANS/DABCYL-based FRET peptide substrate (Ex/Em=340/490 nm upon cleavage) Assay buffer HIV protease inhibitor Fluorescence reference standard for calibration A detailed protocol Kit Size: 500 assays | |
| Detailed Information |  Datasheet Material Safety Data Sheets (MSDS) |
| Product Citations | Shing, CY. et al. (2014). HIV protease: Multiple fold inhibition by silver nanoparticlesSpectrofluorimetric, thermodynamic and kinetic analysis. J Taiwan Inst Chem Eng.Frick, D. et al. (2010). A Method to Simultaneously Monitor Hepatitis C Virus NS3 Helicase and Protease Activities. Meth Mol Biol 587, 223.Yu, Z. et al. (2010). Selective and facile assay of human immunodeficiency virus protease activity by a novel fluorogenic reaction. Anal Biochem 397, 197.Hallengärd, D. et al. (2010). Increased expression and immunogenicity of HIV-1 protease following inactivation of the enzymatic activity. Vaccine 29, 839. |
